The digestive system reactions include nausea, vomiting, and poor appetite, which are lower than those of albumin-paclitaxel (9% vs 18%).[19] Consequently, pm-Pac has been approved by the Chinese Society of Clinical Oncology as a first-line treatment for NSCLC. Here, ALB is linked to non-small cell lung carcinoma.